Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL2 | P60568 | 2/20 | 0.46 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | LCLAT1 | Q6UWP7 | 3/20 | 0.37 |
| ▸ | BACE1 | P56817 | 3/20 | 0.36 |
| ▸ | BACE2 | Q9Y5Z0 | 3/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5046989 | 0.86 | IL2 (0.60) | IL2PTPN11PTPN1LCK | |
| SCHEMBL5051391 | 0.82 | IL2 (0.49) | IL2LCLAT1BACE1BACE2HDAC1 | |
| SCHEMBL5049062 | 0.78 | IL2 (0.51) | IL2PTPN11PTPN1NPC1POLB | |
| SCHEMBL5046976 | 0.78 | IL2 (0.49) | IL2KDM4EBACE1BACE2 | |
| SCHEMBL12848726 | 0.73 | IL2 (0.47) | IL2NPC1POLBRAB9ASMN1; SMN2 | |
| SCHEMBL5051525 | 0.72 | IL2 (0.44) | IL2PTPN11LCK | |
| SCHEMBL31727596 | 0.72 | IL2 (0.46) | IL2SMN1; SMN2KDM4EBACE1BACE2 | |
| SCHEMBL16321002 | 0.70 | IL2 (0.42) | IL2SMN1; SMN2LCK | |
| SCHEMBL5048871 | 0.70 | IL2 (0.44) | IL2PTPN11PTPN1HDAC1HDAC6 | |
| SCHEMBL5046963 | 0.70 | IL2 (0.45) | IL2PTPN11PTPN1NPC1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8455658-B2 | Thiazole and thiadiazole compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2013-06-04 | — | — | US | claimed |
| EP-1983980-A2 | THIAZOLE AND THIADIAZOLE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | Synta Pharmaceuticals Corporation (US) | 2008-10-29 | — | — | EP | claimed |
| US-20070254925-A1 | Thiazole and thiadiazole compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2007-11-01 | — | — | US | claimed |
| WO-2007087427-A2 | THIAZOLE AND THIADIAZOLE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2007-08-02 | — | — | WO | claimed |
| US-20140135331-A9 | THIAZOLE AND THIADIAZOLE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2014-05-15 | — | — | US | disclosed |
| US-20140135331-A9 | THIAZOLE AND THIADIAZOLE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2014-05-15 | — | — | US | disclosed |
| US-20130317032-A1 | THIAZOLE AND THIADIAZOLE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2013-11-28 | — | — | US | disclosed |
| US-8455658-B2 | Thiazole and thiadiazole compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2013-06-04 | — | — | US | disclosed |
| US-8455658-B2 | Thiazole and thiadiazole compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2013-06-04 | — | — | US | disclosed |
| US-8455658-B2 | Thiazole and thiadiazole compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2013-06-04 | — | — | US | disclosed |
| EP-1983980-A2 | THIAZOLE AND THIADIAZOLE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | Synta Pharmaceuticals Corporation (US) | 2008-10-29 | — | — | EP | disclosed |
| US-20070254925-A1 | Thiazole and thiadiazole compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2007-11-01 | — | — | US | disclosed |
| US-20070254925-A1 | Thiazole and thiadiazole compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2007-11-01 | — | — | US | disclosed |
| US-20070254925-A1 | Thiazole and thiadiazole compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2007-11-01 | — | — | US | disclosed |
| WO-2007087427-A2 | THIAZOLE AND THIADIAZOLE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2007-08-02 | — | — | WO | disclosed |
| WO-2007087427-A2 | THIAZOLE AND THIADIAZOLE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2007-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130317032-A1 | THIAZOLE AND THIADIAZOLE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | CXCR1, NLRP3, NLRP1 | IL2 29/4885PTPN11 339/4885PTPN1 94/4885 |
| US-20140135331-A9 | THIAZOLE AND THIADIAZOLE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | CXCR1, NLRP3, NLRP1 | IL2 29/4885PTPN11 339/4885PTPN1 94/4885 |
| US-20070254925-A1 | Thiazole and thiadiazole compounds for inflammation and immune-related uses | CXCR1, NLRP3, NLRP1 | IL2 29/4885PTPN11 339/4885PTPN1 94/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.